1. Mirvetuximab soravtansine-gynx (MIRV), significantly improved progression-free survival, objective response, and overall survival compared to chemotherapy in patients with platinum-resistant, folate receptor alpha (FRĪ±)-positive ovarian cancer 2. Ocular adverse events were more common with MIRV, which included blurry vision, keratopathy, and dry eyes. Evidence Rating: Level 1 (Excellent) Study rundown: Mirvetuximab soravtansine-gynx (MIRV), is an